Sanofi’s progress towards environmental sustainability

This content is for members only.

You need to Login to read the full article. Not a member? Click here to join us and enjoy this content

This content is for members only.

Join The DiscussionCancel reply

Latest posts

From gut resets to microbiome rejuvenation: DDW 2026 highlights transformative approaches to digestive health

An endoscopic procedure that maintains weight loss after stopping GLP-1 drugs, the double hit of stress and late-night eating on gut health, rising rectal cancer deaths in millennials, and youthful microbiome transplants that prevent liver cancer.

May 5, 2026
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML

The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.

January 6, 2026
Novo Nordisk’s denecimig cuts bleeding in hemophilia A regardless of inhibitors

Phase III trial shows once‑monthly and once‑weekly denecimig (Mim8) significantly reduces annualized bleeding rate versus standard care, with up to 95% of patients bleed‑free.

May 5, 2026
Beyond the Snapshot: Continuous physiologic monitoring in clinical trials

Vivalink’s CEO discusses how continuous physiologic monitoring is transitioning from a niche tool for early-stage feasibility studies to a core component of late-stage drug development.

April 16, 2026
Patients open to non-GLP-1 drugs after education, survey finds

A survey finds that while most patients remain unfamiliar with obesity treatments beyond GLP-1s, comprehensive education about alternatives significantly shifts attitudes toward personalized care.

April 9, 2026
ACC26: Amgen’s Repatha cuts first major CV event risk by 31%

New data show Repatha significantly reduces first heart attacks and strokes in high-risk patients without known significant plaque buildup.

April 9, 2026